Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Shorted Shares Decreased By 0.41%

October 2, 2018 - By Peter Kolinski

The stock of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) registered a decrease of 0.41% in short interest. EGRX’s total short interest was 2.58M shares in October as published by FINRA. Its down 0.41% from 2.59 million shares, reported previously. With 215,900 shares average volume, it will take short sellers 12 days to cover their EGRX’s short positions. The short interest to Eagle Pharmaceuticals Inc’s float is 25.47%.

The stock increased 0.69% or $0.465 during the last trading session, reaching $68.195. About 31,617 shares traded. Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has risen 11.00% since October 2, 2017 and is uptrending. It has underperformed by 4.62% the S&P500.

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company has market cap of $1.03 billion. The firm offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It has a 35.59 P/E ratio. The Company’s product candidates includes include EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Ratings Coverage

Among 2 analysts covering Eagle Pharmaceuticals (NASDAQ:EGRX), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Eagle Pharmaceuticals had 5 analyst reports since May 7, 2018 according to SRatingsIntel. Mizuho upgraded the shares of EGRX in report on Monday, June 11 to “Hold” rating. The stock has “Sell” rating by Mizuho on Monday, May 7. Mizuho maintained it with “Sell” rating and $5400 target in Thursday, May 17 report. The stock of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) earned “Overweight” rating by Cantor Fitzgerald on Friday, September 21.

More news for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) were recently published by: Seekingalpha.com, which released: “New operating chief at Eagle Pharma” on September 26, 2018. Streetinsider.com‘s article titled: “Eagle Pharmaceuticals (EGRX) Appoints David Pernock to Position of COO” and published on September 26, 2018 is yet another important article.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News